ArticleMolecular endocrinology (Baltimore, Md.)2008
Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.
Article in Molecular endocrinology (Baltimore, Md.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Silent corticotroph adenomas.Pituitary · 2015Pooled it
- Paracrine FGF1 signaling directs pituitary architecture and size.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Pituitary cell translation and secretory capacities are enhanced cell autonomously by the transcription factor Creb3l2.Nature communications · 2019Article
- Pioneer and nonpioneer factor cooperation drives lineage specific chromatin opening.Nature communications · 2019Article
- Stem Cells, Self-Renewal, and Lineage Commitment in the Endocrine System.Frontiers in endocrinology · 2019Review
- Single-Cell RNA Sequencing Reveals Novel Markers of Male Pituitary Stem Cells and Hormone-Producing Cell Types.Endocrinology · 2018Article
- Pioneer factor Pax7 deploys a stable enhancer repertoire for specification of cell fate.Nature genetics · 2018Article
- Genetic regulation of murine pituitary development.Journal of molecular endocrinology · 2015Review
- Adult pituitary cell maintenance: lineage-specific contribution of self-duplication.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Pituitary gland development and disease: from stem cell to hormone production.Current topics in developmental biology · 2013Review
- The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling.Genes & development · 2012Article
- Subclinical hyperfunctioning pituitary adenomas: the silent tumors.Best practice & research. Clinical endocrinology & metabolism · 2012Review
- Article
- Related pituitary cell lineages develop into interdigitated 3D cell networks.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- The Ets factor Etv1 interacts with Tpit protein for pituitary pro-opiomelanocortin (POMC) gene transcription.The Journal of biological chemistry · 2011Article
- A pituitary-specific enhancer of the POMC gene with preferential activity in corticotrope cells.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis.Molecular endocrinology (Baltimore, Md.) · 2010Article
- Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes.Molecular and cellular endocrinology · 2010Review
- Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.Hormones & cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-specific expression of the pituitary proopiomelanocortin (POMC) gene depends on the combinatorial action of a large number of DNA-binding transcription factors (TFs). These include general and cell-restricted factors, as well as factors that act as effectors of signaling pathways. We have previously defined in the distal POMC promoter a composite regulatory element that contains targets for basic helix-loop-helix TFs conferring cell specificity and for NGFI-B orphan nuclear receptors that are responsive to CRH signaling and to glucocorticoid negative feedback. These factors act on neighboring regulatory elements, the Ebox(Neuro) and NurRE, respectively. Currently, the Ebox(Neuro) is thought to be the target of NeuroD1 during fetal development, but this factor may not account for activity in the adult pituitary; it is also unknown whether the NurRE and NGFI-B-related factors are active before establishment of the hypothalamic-pituitary portal system. In order to assess the importance of these regulatory elements and their cognate TFs throughout pituitary organogenesis and in the adult, we have assessed the activity of mutant POMC promoters in transgenic mice throughout development. These experiments indicate that the Ebox(Neuro) and cognate basic helix-loop-helix factors are required throughout development and in the adult gland, beyond expression of NeuroD1. Similarly, the data reveal sustained importance of the NurRE and its cognate factors throughout pituitary development. These data contrast the sustained dependence throughout development on the same regulatory elements with the highly dynamic patterns of TF expression and the modulation of their activity in response to signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.